Anthropic details Claude’s role in antibody design and drug development
Anthropic describes Claude-assisted work on antibody design, CAR T-cell components and clinical-trial planning. One food-allergy programme generated 35,000 antibody designs; the report also covers BigHat optimisation and Bristol Myers Squibb’s trial-planning work.
Generate Biomedicines scientists used Claude Code to design a shorter genetic component for CAR T-cell therapy, freeing space for instructions intended to help tackle solid tumours. In lab tests, one design produced roughly ten times as many cancer-spotting receptors, improved tumour-cell killing and kept immune cells active longer.
BigHat tested about 1,010 antibody-fragment variants over ten weeks using Claude to propose changes. The best variants bound their targets more than ten times as tightly; a cancer-targeting lead stayed in solution at temperatures 18°C higher, while another lead clumped more than 100 times more slowly.
Bristol Myers Squibb is using Claude to assess an early-stage drug’s clinical-trial plans and estimate their chances of success. It and Anthropic plan to expand the work in 2027 to explore whether it can improve early-development success rates.
Anthropic’s Life Sciences Verification Program allows trusted organisations to use its most powerful models with more permissive safeguards. The programme addresses restrictions that can impede legitimate biological research.